Kanaph Therapeutics

Kanaph Therapeutics is a leading player in next-generation immuno-oncology and autoimmune disease therapeutics. Established in 2019 in South Korea, the company focuses on drug discovery and pre-clinical stage biotech with a dual-track strategy for large and small molecule development. Their goal is to create first-in-class and best-in-class therapeutics for immuno-oncology, targeted therapy, and autoimmune diseases, particularly in ophthalmology. The company's oncology pipeline boasts bi-specific antibodies and small molecules that demonstrate significantly improved immuno-stimulatory activity within the tumor micro-environment to effectively eradicate tumors. Simultaneously, their autoimmune disease pipeline includes bispecific Fc-fusions designed to inhibit the alternative complement pathway, angiogenesis, and downstream complement activation. Kanaph recently secured a $21.00M Series B investment on October 12, 2020. The investment was led by Kolon Investment, Timepolio Asset Management, and Green Cross. With its innovative approach to tackling critical medical challenges and significant investment backing, Kanaph Therapeutics is poised to make a substantial impact within the biotechnology and pharmaceutical industries.